Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
This is a defining moment for the company’s integrity, long-term viability, and moral compass. The core tension is between short-term financial protection and long-term trust, legal exposure, and—most importantly—patient safety. Ethically and legally, the company has a duty to act on credible safety signals.Read the full answer
As CEO, my primary fiduciary and ethical duty is to patients, regulators, and long-term shareholder value. The "6-month reporting timeline" cited by legal is almost certainly a misunderstanding of regulatory processes (likely conflating initial adverse event reporting with full label amendment review).Read the full answer